Millipore Sigma Vibrant Logo

557324 Riluzole - CAS 1744-22-5 - Calbiochem

A cell-permeable benzothiazole compound that potently inhibits glutamate release and blocks Na+ channels.

Riluzole - CAS 1744-22-5 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: 2-Amino-6-(trifluoromethoxy)benzothiazole, PK 26124

Primary Target: Inhibits glutamate release and blocks Na+ channels
View Products on Sigmaaldrich.com
557324
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
1744-22-5C₈H₅F₃N₂OS

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
557324-50MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Bidon alu 50 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewA cell-permeable benzothiazole compound that potently inhibits glutamate release and blocks Na+ channels. Shown to function as a polyglutamine aggregation inhibitor and stimulates the synthesis of NGF, BDNF, and GDNF in mouse astrocyte cultures. Reported to offer neuroprotection, slow down disease progression in ALS (amyotrophic lateral sclerosis) patients, and prolong the lifespan of animal models of HD (Huntington’s disease).
      Catalogue Number557324
      Brand Family Calbiochem®
      Synonyms2-Amino-6-(trifluoromethoxy)benzothiazole, PK 26124
      References
      ReferencesHeiser, V., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 16400.
      Schiefer, J., et al. 2002. Mov. Disord. 17, 748.
      Mizuta, I., et al. 2001. Neurosci. Lett. 310, 117.
      Louvel, E., et al. 1997. Trends Pharmacol. Sci. 18, 196.
      Mizoule, J., et al. 1985. Neuropharmacology 24, 767.
      Product Information
      CAS number1744-22-5
      ATP CompetitiveN
      FormWhite to off-white solid
      Hill FormulaC₈H₅F₃N₂OS
      Chemical formulaC₈H₅F₃N₂OS
      ReversibleN
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetInhibits glutamate release and blocks Na+ channels
      Purity≥97% by HPLC
      Physicochemical Information
      Cell permeableY
      ContaminantsHeavy metals: ≤20 ppm
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSDL2830000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Toxic
      Hazardous Materials Attention: Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      557324-50MG 04055977267938

      Documentation

      Riluzole - CAS 1744-22-5 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Riluzole - CAS 1744-22-5 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      557324

      Références bibliographiques

      Aperçu de la référence bibliographique
      Heiser, V., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 16400.
      Schiefer, J., et al. 2002. Mov. Disord. 17, 748.
      Mizuta, I., et al. 2001. Neurosci. Lett. 310, 117.
      Louvel, E., et al. 1997. Trends Pharmacol. Sci. 18, 196.
      Mizoule, J., et al. 1985. Neuropharmacology 24, 767.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision19-May-2008 RFH
      Synonyms2-Amino-6-(trifluoromethoxy)benzothiazole, PK 26124
      DescriptionA cell-permeable benzothiazole compound that potently inhibits glutamate release and blocks Na+ channels. Reported to function as a polyglutamine aggregation inhibitor and stimulate the synthesis of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell-derived neurotrophic factor (GDNF) in mouse astrocyte cultures. Offers neuroprotection, slows disease progression in amyotrophic lateral sclerosis (ALS) patients, and prolongs survival in animal models of Huntington's disease (HD).
      FormWhite to off-white solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number1744-22-5
      RTECSDL2830000
      Chemical formulaC₈H₅F₃N₂OS
      Purity≥97% by HPLC
      ContaminantsHeavy metals: ≤20 ppm
      SolubilityDMSO (40 mg/ml) or HCl (0.1N)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Toxic
      Merck USA index14, 8223
      ReferencesHeiser, V., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 16400.
      Schiefer, J., et al. 2002. Mov. Disord. 17, 748.
      Mizuta, I., et al. 2001. Neurosci. Lett. 310, 117.
      Louvel, E., et al. 1997. Trends Pharmacol. Sci. 18, 196.
      Mizoule, J., et al. 1985. Neuropharmacology 24, 767.